Efficacy and safety of combined treatment with tranexamic acid and erythropoietin during surgery for intertrochanteric fractures

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000039879

Enrollment

Unknown

Registered

2020-11-13

Start date

2020-11-25

Completion date

Unknown

Last updated

2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

intertrochanteric fractures

Interventions

Group 1:tranexamic acid

Group 2:tranexamic acid and erythropoietin

Group 3:Nil

Eligibility

Sex/Gender

All

Age

60 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Unilateral intertrochanteric fracture; 2. Aged 60-85 years; 3. Hemoglobin in 60-90g / L; 4. No tumor, tuberculosis and hematological diseases.

Exclusion criteria

Exclusion criteria: Combined with tumor, tuberculosis and hematological diseases.

Design outcomes

Primary

Measure	Time frame
hemoglobin;Amount of bleeding;Amout of incision drainage;Blood transfusion volume;Incidence of thrombosis;Length of stay;	—

Countries

China

Contacts

Public ContactChao Sun

The Affiliated Jiangning Hospital with Nanjing Medical University

desunchao@njmu.edu.cn+86 15005183384

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026